Veracyte (VCYT) Competitors $33.23 +1.40 (+4.40%) Closing price 04:00 PM EasternExtended Trading$33.23 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VCYT vs. ADPT, BEAM, GH, TWST, TXG, RDNT, OPCH, SHC, BTSG, and WGSShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Adaptive Biotechnologies (ADPT), Beam Therapeutics (BEAM), Guardant Health (GH), Twist Bioscience (TWST), 10x Genomics (TXG), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), and GeneDx (WGS). These companies are all part of the "medical" sector. Veracyte vs. Its Competitors Adaptive Biotechnologies Beam Therapeutics Guardant Health Twist Bioscience 10x Genomics RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Veracyte (NASDAQ:VCYT) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings. Does the media prefer VCYT or ADPT? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Veracyte. MarketBeat recorded 6 mentions for Adaptive Biotechnologies and 2 mentions for Veracyte. Veracyte's average media sentiment score of 1.68 beat Adaptive Biotechnologies' score of 1.14 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in VCYT or ADPT? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is VCYT or ADPT more profitable? Veracyte has a net margin of 5.50% compared to Adaptive Biotechnologies' net margin of -59.07%. Veracyte's return on equity of 6.07% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Veracyte5.50% 6.07% 5.53% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has more volatility & risk, VCYT or ADPT? Veracyte has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Do analysts rate VCYT or ADPT? Veracyte currently has a consensus price target of $40.90, suggesting a potential upside of 23.08%. Adaptive Biotechnologies has a consensus price target of $12.38, suggesting a potential downside of 10.13%. Given Veracyte's higher probable upside, equities research analysts plainly believe Veracyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has better earnings & valuation, VCYT or ADPT? Veracyte has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$445.76M5.86$24.14M$0.33100.70Adaptive Biotechnologies$178.96M11.72-$159.49M-$0.82-16.79 SummaryVeracyte beats Adaptive Biotechnologies on 11 of the 16 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.61B$6.83B$5.81B$10.36BDividend YieldN/A1.14%5.86%4.62%P/E Ratio100.7027.0876.8826.91Price / Sales5.86175.01449.1488.66Price / Cash31.1321.7137.2260.63Price / Book2.195.0113.796.37Net Income$24.14M$178.07M$3.29B$271.46M7 Day Performance4.30%5.63%0.93%2.33%1 Month Performance10.51%8.58%5.32%7.78%1 Year Performance-1.57%19.40%84.26%31.12% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.8169 of 5 stars$33.23+4.4%$40.90+23.1%-7.3%$2.61B$445.76M100.70790Positive NewsADPTAdaptive Biotechnologies3.4713 of 5 stars$12.54-2.4%$12.38-1.3%+176.9%$1.96B$178.96M-15.29790Positive NewsBEAMBeam Therapeutics3.2054 of 5 stars$19.94-4.5%$48.45+143.0%-12.2%$2.11B$63.52M-4.43510Analyst ForecastGap UpGHGuardant Health3.6811 of 5 stars$60.17+0.1%$58.24-3.2%+127.9%$7.50B$739.02M-17.962,021Insider TradeTWSTTwist Bioscience4.0133 of 5 stars$26.25+1.9%$49.40+88.2%-43.4%$1.55B$312.97M-18.10990Gap UpTXG10x Genomics3.5531 of 5 stars$13.93-0.2%$13.54-2.8%-39.9%$1.74B$610.78M-19.901,240Gap UpRDNTRadNet3.2675 of 5 stars$71.99+0.8%$76.80+6.7%+12.6%$5.49B$1.83B-359.9311,021Positive NewsOPCHOption Care Health4.8793 of 5 stars$29.59+1.7%$35.75+20.8%-10.3%$4.72B$5.00B23.678,088Positive NewsSHCSotera Health2.2414 of 5 stars$15.91+1.9%$16.00+0.6%-2.5%$4.44B$1.10B198.903,000High Trading VolumeBTSGBrightSpring Health Services2.3036 of 5 stars$25.48+5.6%$25.67+0.7%+87.2%$4.27B$11.27B32.6135,000High Trading VolumeWGSGeneDx2.6454 of 5 stars$129.33-2.4%$101.63-21.4%+244.4%$3.81B$305.45M2,586.601,200Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Competitors Beam Therapeutics Competitors Guardant Health Competitors Twist Bioscience Competitors 10x Genomics Competitors RadNet Competitors Option Care Health Competitors Sotera Health Competitors BrightSpring Health Services Competitors GeneDx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCYT) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCYT Stock Alerts